NCHR Testimony at FDA on Gastric LAP-BAND

December 3, 2010. In their newly proposed label, Allergan indicated a “caution” (not a warning) for patients with autoimmune diseases or symptoms, and did NOT mention a family history of those conditions.

Read More »

NCHR Testimony at the FDA Advisory Committee Meeting on Lorcaserin

September 16, 2010. The studies are an important reminder that behavior modification is a safe and effective alternative to diet pills. Lorcaserin does not appear to be effective for most patients, and especially not for most African-American or Latino patients. More extensive research is needed on the risks.

Read More »